Early non-convulsive seizures are associated with the development of acute encephalopathy with biphasic seizures and

Azusa Maruyama1, Shoichi Tokumoto2, Hiroshi Yamaguchi2

  • 1Department of Neurology, Hyogo Prefectural Kobe Children's Hospital, Japan.

Brain & Development
|December 21, 2020
PubMed

Insights

Non-convulsive seizures (NCS) are common in children at high risk for acute encephalopathy with biphasic seizures and late reduced diffusion (AESD). Early detection of NCS via cEEG is crucial as it is linked to worse neurological outcomes and AESD development.

Area of Science:

  • Pediatric Neurology
  • Neurophysiology
  • Critical Care Medicine

Background:

  • Febrile seizures and acute encephalopathy in children can present with seizures and fever of unknown etiology (SICF).
  • Children with SICF, particularly those with refractory status epilepticus or prolonged neurological abnormalities, face a high risk of developing acute encephalopathy with biphasic seizures and late reduced diffusion (AESD).
  • Non-convulsive seizures (NCS) are prevalent in critically ill children and contribute to excitotoxic neuronal injury.

Purpose of the Study:

  • To determine the prevalence of NCS in the acute phase of high-risk pediatric patients for AESD.
  • To investigate the association between acute-phase NCS and subsequent neurological outcomes, including AESD development.

Main Methods:

  • A cohort of 137 children at high risk for AESD and presenting with SICF were studied.
  • Continuous electroencephalogram monitoring (cEEG) was performed upon admission.
  • Patient characteristics and outcomes were compared between those with and without NCS.

Main Results:

  • NCS were detected in 30 out of 137 children, with 96.7% detected within 12 hours of admission.
  • Neurological sequelae were significantly more common in children with NCS (20.0%) compared to those without (1.9%).
  • AESD developed in 16.7% of NCS patients versus 2.8% of non-NCS patients.

Conclusions:

  • The presence of NCS in the acute phase is a significant risk factor for neurological sequelae.
  • NCS occurrence is strongly associated with the subsequent development of AESD in high-risk children.
Abstract

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.0K
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
905
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
440
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
627